Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104836 | 0.91 | APP (0.48) | APPBCHEACHEMEN1KMT2A | |
| SCHEMBL9235295 | 0.89 | APP (0.41) | APPBCHEACHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9236979 | 0.88 | APP (0.40) | APPBCHEACHEMEN1KMT2A | |
| SCHEMBL9236363 | 0.87 | APP (0.42) | APPBCHEACHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9232944 | 0.86 | APP (0.41) | APPBCHEACHEMEN1KMT2A | |
| SCHEMBL9237808 | 0.85 | APP (0.40) | APPBCHEACHEMEN1KMT2A | |
| SCHEMBL9238122 | 0.85 | APP (0.40) | APPBCHEACHEMEN1KMT2A | |
| SCHEMBL9104296 | 0.85 | BCDIN3D (0.42) | APPBCHEACHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9102361 | 0.84 | APP (0.40) | APPBCHEACHEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9239012 | 0.84 | APP (0.40) | APPBCHEACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118829433-A | Respiratory stimulant parenteral formulations | 依那拉治疗股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118488840-A | Methods of treating respiratory depression modulated by non-opioid agents | 依那拉治疗股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-117479945-A | Large conductance potassium channel modulators, compositions thereof, methods of making and methods of using the same | 依那拉治疗股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-114173872-A | Methods and pharmaceutical compositions for treating drug overdose | 依那拉治疗股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2013181217-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| CN-103347866-A | Novel compound as respiratory stimulants for treatment of breathing control disorder or disease | GALLEON PHARMACEUTICALS INC | 2013-10-09 | — | — | CN | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | APP 3078/4885BCHE 119/4885ACHE 75/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | APP 2477/4885BCHE 238/4885ACHE 266/4885 |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, MTNR1B, NDUFB5 | APP 2437/4885BCHE 176/4885ACHE 139/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | APP 3010/4885BCHE 591/4885ACHE 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.